CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

208026Orig1s000

SUMMARY REVIEW

Cross-Discipline Team Leader Review

Date	23 May 2016
From	Lisa Yanoff, M.D.
Subject	Cross-Discipline Team Leader Review
NDA/BLA #	208026
Applicant	Boehringer Ingelheim Pharmaceuticals, Inc.
Date of Submission	27 Jul 2015
PDUFA Goal Date	27 May 2016
Proprietary Name / Established (USAN) names	Jentadueto XR/ Linagliptin and metformin hydrochloride extended-release
Dosage forms / Strength	Oral tablets with the following dosage strengths: 5 mg linagliptin/1000 mg metformin hydrochloride extended-release 2.5 mg linagliptin/1000 mg metformin hydrochloride extended-release
Proposed Indication(s)	as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate
Recommended:	Approval

Cross Discipline Team Leader Review

1. Introduction

Boehringer Ingelheim Pharmaceuticals, Inc. is submitting a New Drug Application (NDA) #208026 under section 505(b)(1) of the Federal Food, Drug and Cosmetic Act for the fixed-combination drug product linagliptin /metformin hydrochloride extended-release for the treatment of patients with type 2 diabetes mellitus (T2DM).

The regulatory pathway through section 505(b)(1) is appropriate because the Applicant is the sponsor of the linagliptin product (Tradjenta, NDA 201280) and provides a Letter of Authorization from the sponsor of the metformin extended-release product (Glumetza, NDA 021748).

The proposed indication is an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

2. Background and Application Overview

The NDA is for linagliptin/metformin extended release, a fixed combination drug [also known as a fixed-dose combination (FDC)] of linagliptin, a dipeptidyl peptidase 4 inhibitor (DPP4-i) and metformin, the only member of the biguanide class. Both components are approved in the U.S. as individual products, and an immediate release formulation of the combination is also approved in the U.S. and marketed as Jentadueto. The proposed trade name Jentadueto XR has been determined to be acceptable by the Division of Metabolism and Endocrinology Products and by the Division of Medication Error and Prevention Analysis and will be used interchangeably with the nonproprietary name throughout this memo.

Linagliptin is the third DPP4-i approved in the U.S. Linagliptin improves glycemic control in patients with type 2 diabetes mellitus (T2DM) by inhibiting the inactivation of GLP-1 and GIP (incretin hormones) and prolonging the incretin effect on beta cells (serum glucose-dependent insulin stimulation) and alpha cells (glucagon suppression). GLP-1 in particular has other effects that contribute to improved glucose control in diabetics, such as appetite suppression and slowing of the rate of gastric emptying. Linagliptin is dosed at 5 mg once daily.

Metformin is effective in decreasing hepatic glucose output and decreasing peripheral glucose utilization. Metformin gained a first-line treatment recommendation by the American Diabetes Association and other diabetes professional organizations, and is widely used in the treatment of T2DM. The Prescribing Information for Glumetza (metformin XR) states that '*in general, clinically significant responses are not seen at doses below 1500 mg per day. However, a lower recommended starting dose and gradually increased dosage is advised to minimize gastrointestinal symptoms. The starting dose of GLUMETZA is 1000 mg once daily which in order to maximize therapeutic efficacy must be taken with food preferably in the evening. Dosage increases should be made in increments of 500 mg weekly, up to a maximum of 2000*

mg once daily with the evening meal. If glycemic control is not achieved on GLUMETZA 2000 mg once daily, a trial of GLUMETZA 1000 mg twice daily should be considered.'

The proposed strengths for Jentadueto XR are 5 mg linagliptin/1000 mg metformin hydrochloride extended-release 2.5 mg linagliptin/1000 mg metformin hydrochloride extended-release. The proposed dosing regimen is as follows:

- in patients currently not treated with metformin, initiate treatment with 5 mg linagliptin/1000 g metformin hydrochloride extended-release once daily (b) (4)
- In patients already treated with metformin, the (b) (4) total daily starting dose of JENTADUETO XR is 5 mg linagliptin and a similar total daily dose of metformin
- In patients already treated with TRADJENTA and metformin or JENTADUETO switch to JENTADUETO XR containing 5 mg of linagliptin total daily dose and a similar total daily dose of metformin

In addition to adequate clinical trial data, approval of an FDC for the treatment of T2DM is dependent on demonstration of bioequivalence (BE) of the FDC and the two individual components administered together. With demonstration of BE, the precedent within the Division of Metabolism and Endocrinology Products for products containing metformin combined with another oral antidiabetic agent is to then approve the FDC for either a 'narrow' indication (e.g. patients *who are not adequately controlled on a regimen containing metformin or linagliptin, or in patients who are already treated with both linagliptin and metformin*) or a 'broad' indication (e.g. *when treatment with both linagliptin and metformin is appropriate*). The narrow indication is typically granted based on clinical trial data showing additional placebo-adjusted glycemic lowering from the second drug (e.g. linagliptin) to metformin. To allow treatment with the FDC in patients who are treatment naïve, the applicant must show that the coadministration (or alternatively, the FDC) is more effective than each component alone, in patients not treated with either drug prior to the trial, i.e. show contribution of claimed effect of each component as per 21CFR 300.50. The typical approach is to conduct a factorial study with each of the single agents being compared to the combination; such a study was submitted with the original Jentadueto NDA and was used to support the initial approval of Jentadueto with the broader indication.

The basis for the request for approval of the proposed (broad) indication for Jentadueto XR is the following:

- Results of the pivotal bioequivalence (BE) studies
- Clinical comparability between metformin twice daily (Glucophage) and once daily (Glumetza) shown in the original NDA for Glumetza
- The efficacy and safety of co-administration of linagliptin and metformin twice daily (Glucophage) as add-on to metformin in the original Tradjenta NDA and as initial therapy in the factorial study 1218.46 submitted to support the approval of Jentadueto for the 'broad' indication

This summary memo contains a high-level overview of the important review findings of the NDA. Please see the individual reviews for each discipline for detailed discussions. This memo references the following documents.

Subject	Author	Date in DARRTS
Clinical Pharmacology (OCP) review	Dr. Sang Chung and Dr. Manoj Khurana	27 Apr 2016
Chemistry Manufacturing and Controls (Quality) review	Team review, Technical Lead Dr. Suong Tran	18 Apr 2016 (in Panorama)
Clinical Efficacy and Safety Review	Dr. Hyon Kwon	18 May 2016
Nonclinical review (Pharmacology/toxicology)	Dr. David Carlson	20 Apr 2016
Division of Pediatric and Maternal Health consult	Dr. Miriam Dinatale	28 Apr 2016
Office of Study Integrity and Surveillance inspection reviews	Dr. Li-Hong Paul Yeh	19 Feb 2016, 11 Mar 2016, 15 Mar 2016
Division of Medication Error Prevention and Analysis consult review	Dr. Sarah Vee and Dr. Yelena Maslov	29 Apr 2016
Division of Medical Policy Programs (DMPP) consult review	Team review	5 May 2016

3. CMC

The recommendation from the Office of Pharmaceutical Quality (including the Overall Manufacturing Inspection Recommendation) is approval. NDA 201280 Tradjenta (linagliptin), by the same applicant, is referenced for all CMC information on the drug substance linagliptin. The NDA is currently approved and the reference is adequate. NDA 201281 Jentadueto (linagliptin/metformin HCl), by the same applicant, is referenced for all CMC information on the drug substance metformin HCl. The NDA is currently approved and the reference is adequate.

The drug product is a film-coated tablet consisting of immediate release linagliptin and extended release metformin HCl, with two strengths: 5 mg/1000 mg and 2.5 mg/1000 mg linagliptin (immediate release)/metformin hydrochloride (extended release). Please see the Quality review for details.

4. Nonclinical Pharmacology/Toxicology

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.